Iterum Therapeutics PLC

NASDAQ ITRM

Download Data

Iterum Therapeutics PLC Market Capitalization on June 03, 2024: USD 23.67 M

Iterum Therapeutics PLC Market Capitalization is USD 23.67 M on June 03, 2024, a 51.91% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.
  • Iterum Therapeutics PLC 52-week high Market Capitalization is USD 30.86 M on November 24, 2023, which is 30.37% above the current Market Capitalization.
  • Iterum Therapeutics PLC 52-week low Market Capitalization is USD 8.72 M on October 25, 2023, which is -63.15% below the current Market Capitalization.
  • Iterum Therapeutics PLC average Market Capitalization for the last 52 weeks is USD 18.14 M.
NASDAQ: ITRM

Iterum Therapeutics PLC

CEO Mr. Corey N. Fishman
IPO Date May 25, 2018
Location Ireland
Headquarters Fitzwilliam Court, Dublin, Ireland, 2
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Similar companies

HOTH

Hoth Therapeutics Inc

USD 1.17

0.00%

StockViz Staff

July 27, 2024

Any question? Send us an email